Category Archives: Uncategorized

Cardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated Balloon

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the start of enrollment in a first in-human trial of the coronary everolimus … Continue reading

Posted in Uncategorized | Leave a comment

Restore Medical Announces First in Human Trial for Treatment of Heart Failure in Patients

ContraBand™ technology helps restore the heart’s functionality and may significantly improve patients’ quality of life OR YEHUDA, Israel, Dec. 7, 2021 /PRNewswire/ — Restore Medical Ltd., a clinical-stage MedTech company developing cardiac implants for the treatment of congestive heart failure (CHF), today announced promising … Continue reading

Posted in Uncategorized | Leave a comment

Congress CSI Focus D-HF, Frankfurt, Germany, December 10-11th 2021

Clinical Accelerator is proud to have sponsored the CSI Focus D-HF (Device therapies in heart failure) conference this year in Frankfurt, Germany. Organized by Dr Horst Sievert, the two-day conference was one of the first to be in person in … Continue reading

Posted in Uncategorized | Leave a comment

Anteris Technologies CEO talks ‘outstanding results’ from first human DurAVR patients

Anteris Technologies CEO talks ‘outstanding results’ from first human DurAVR patients

Posted in Uncategorized | Leave a comment

Clinical Accelerator collaborates with CroíValve on a study for Tricuspid Regurgitation

  Clinical Accelerator has recently entered into a new collaboration with CroíValve – a medical device company from Ireland – who is developing a novel, easy to use percutaneous solution for treating patients with severe Tricuspid Regurgitation (TR). Tricuspid Regurgitation … Continue reading

Posted in Uncategorized | Leave a comment

VisCardia Announces Its Novel Heart Failure Therapy Receives Breakthrough Device Designation From the FDA

Below, we are re-publishing with permission the press-release issued by VisCardia Inc. on April 23, 2020 PORTLAND, Ore., April 23, 2020 (Newswire.com) – VisCardia Inc., a privately held medical device developer, announced today it has been granted Breakthrough Device Designation … Continue reading

Posted in Uncategorized | Leave a comment

Clinical Accelerator announces collaboration with Nasaleze International Ltd for a clinical study of Nasafort- a fast acting nasal spray for allergic rhinitis

Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Nasaleze International Limited, for conducting a pivotal study for Nasafort: a nasally applied cellulose powder in seasonal allergic rhinitis (SAR) in … Continue reading

Posted in Uncategorized | Leave a comment

DARRT-1 CLINICAL STUDY COMMENCES

Below, we are re-publishing with permission the press-release issued by Noxopharm Limited on the 5th of April 2018      • Multi-national study testing ability of NOX66 to enhance radiotherapy      • First cohort of patients treated      • Direct … Continue reading

Posted in Uncategorized | Leave a comment

Brexit and Clinical Trials_Part 1

Well, the people of Britain have now spoken – albeit not that clearly given a 51.9%:48.1% split in the referendum voting figures. Nevertheless, it’s a democratic decision and now the word on almost everyone’s lips is “Brexit”. Despite a protest … Continue reading

Posted in European Union, Uncategorized | Leave a comment

Statistical Controversies in Reporting of Clinical Trials

In one of the recent issues of the Journal of the American College of Cardiology, Professor Stuart Pocock and colleagues discussed controversies in reporting clinical trial results.  Prof. Pocock is a well-known biostatistician from the Department of Medical Statistics at … Continue reading

Posted in Uncategorized | Leave a comment